VMB-C001a

VMB-C001a is an investigational, long-acting, caninized anti-interleukin-23 (IL-23) monoclonal antibody being developed by VETmAb Biosciences. It is designed to target IL-23, a key cytokine that acts as a master regulator of intestinal inflammation, to treat canine chronic inflammatory enteropathy (CIE), also known as inflammatory bowel disease (IBD) in dogs. Administered via intravenous or subcutaneous injection, VMB-C001a has demonstrated positive clinical proof-of-concept in a randomized, placebo-controlled pilot study in dogs with naturally occurring CIE, showing a 77.8% treatment success rate compared to 30.0% for placebo. The U.S. FDA Center for Veterinary Medicine (CVM) has granted VMB-C001a eligibility for the expanded conditional approval (XCA) pathway, and the company plans to advance the candidate into pivotal clinical development.